Harmful inflammation in multiple sclerosis patients is effectively suppressed by administration of anti-CD20 biologics modulating mature B cells. Does the route of their administration matters?

Abstract

Multiple sclerosis (MS) is an immunopathological neurodegenerative disease in the pathogenesis of which damaging inflammation plays a significant role. It is characterized by the abnormal activity of functionally polarized Th1 and Th17 lymphocytes with a significant proportion of the B lymphocyte system.

Keywords

• Multiple sclerosis
• damaging inflammation
• B lymphocytes
• anti-CD20 biologics
• the FcRn receptor